Amyloid-beta (Aβ)

Overview

Amyloid-beta (Aβ) is a peptide fragment derived from the proteolytic processing of the Amyloid Precursor Protein (APP))))))), encoded by the APP gene on chromosome 21. It is a 40-42 amino acid peptide that plays a central role in the pathogenesis of Alzheimer’s disease (AD) and related amyloidopathies^{1Hardy & Selkoe, The amyloid hypothesis of Alzheimer's disease (2002)2002 · DOI 10.1126/science.1072994Open reference}.

Amyloidogenic Processing

APP Processing Pathway

flowchart TD
    APP["APP Protein"] --> B{"Non-amyloidogenic"}
    APP --> C{"Amyloidogenic"}

    B --> D["alpha-secretase cleavage"]
    D --> E["sAPPalpha<br/>Neuroprotective"]
    D --> F["CTF-alpha"]

    C --> G["beta-secretase BACE1"]
    G --> H["sAPPbeta"]
    G --> I["CTF-beta"]
    I --> J["gamma-secretase"]
    J --> K["Abeta monomers"]

    K --> L["Oligomers"]
    L --> M["Protofibrils"]
    M --> N["Fibrils"]
    N --> O["Amyloid Plaques"]

    K -->|"Abeta40 ~80-90%"| P["Less aggregation-prone"]
    K -->|"Abeta42 ~5-10%"| Q["More toxic"]

    L -->|"Toxic"| R["Synaptic Dysfunction"]
    L -->|"Toxic"| S["Oxidative Stress"]
    L -->|"Toxic"| T["Calcium Dysregulation"]
    L -->|"Toxic"| U["Neuroinflammation"]

    style D fill:#0e2e10,stroke:#2e7d32
    style G fill:#3b1114,stroke:#c62828
    style O fill:#3b1114,stroke:#c62828

APP can be processed through two mutually exclusive pathways:

1. Non-amyloidogenic pathway: alpha-secretase cleaves APP within the Abeta sequence, precluding Abeta formation. This pathway produces soluble APPalpha (sAPPalpha) and a membrane-bound C-terminal fragment.

2. Amyloidogenic pathway: beta-secretase (BACE1) cleaves APP at the N-terminus of Abeta, followed by gamma-secretase cleavage at the C-terminus, releasing Abeta peptides of various lengths (Abeta38, Abeta40, Abeta42, Abeta43)^{2O'Brien & Wong, Amyloid precursor protein processing and Alzheimer's disease (2011)2011 · DOI 10.1146/annurev-neuro-030514-124328Open reference}.

The Abeta42 isoform is more hydrophobic and aggregation-prone than Abeta40, making it the primary species found in amyloid plaques.

See also: APP Amyloid Pathway.

Molecular Structure

Primary Sequence and Domains

Amyloid-beta peptides are derived from the transmembrane domain of APP, with the Aβ sequence spanning residues 681-770 of the APP770 isoform. The peptide contains:

• N-terminal region (1-16): Highly hydrophilic, forms the “soft” segment that initiates aggregation

• Central hydrophobic core (17-21, KLVFF): Critical for fibril formation, known as the “KLVFF” motif

• C-terminal region (22-40/42): Hydrophobic, drives membrane association and aggregation

Secondary and Tertiary Structure

In solution, monomeric Aβ adopts a random coil conformation. Upon aggregation, it transitions to:

• β-sheet structure: Cross-β architecture with strands perpendicular to the fibril axis

• Hydrophobic interactions: Drive the formation of the steric zipper

• Salt bridges: Stabilize the fibril core (e.g., D23-K28 ionic interaction)

Cryo-EM studies have revealed multiple Aβ42 fibril morphologies:

• 3-fold symmetric protofilaments (common in sporadic AD)

• 2-fold symmetric dimers (familial AD cases)

• Polymorphic strains: Different conformations associated with distinct disease phenotypes

Available PDB structures include: 1IYT, 1BA4, 2BEG, 5OQV, 7JTL, 7JYY.

The protein’s three-dimensional structure can also be explored via the AlphaFold Protein Structure Database.

Post-Translational Modifications

Aβ undergoes numerous PTMs that modulate its aggregation and toxicity:

Phosphorylation

• Ser8: phosphorylation reduces aggregation

• Ser26: affects membrane interactions

• Tyrosine10: nitration enhances toxicity

Truncation

• N-terminally truncated species (AβpE3, AβpE11): More aggregation-prone, found in plaques

• C-terminally truncated species (Aβ1-38): Less toxic, may be protective

Isomerization

• Asp7 isomerization: Affects aggregation kinetics

• Asp23 isomerization: Alters fibril structure

Oxidation

• Methionine35 oxidation: Reduces aggregation but increases toxicity of oligomers

• Histidine oxidation: Modifies metal binding

Glycation

• Advanced glycation end products (AGEs): Cross-link Aβ, enhance aggregation

• Found in AD brain: Correlates with disease severity

Aggregation and Toxicity

Nucleation-Dependent Polymerization

Aβ aggregation follows a nucleation-dependent polymerization mechanism (also called “seeded growth”):

1. Lag phase: Monomers slowly form unstable oligomers

2. Nucleation: Critical nucleus forms (typically 2-6 monomers)

3. Elongation: Rapid addition of monomers to seed

4. Saturation: Equilibrium between monomers and fibrils

flowchart TD
    A["Abeta Monomers"] --> B["Lag Phase"]
    B --> C["Nucleation<br/>Critical Seed"]
    C --> D["Elongation Phase"]
    D --> E["Protofibrils"]
    E --> F["Mature Fibrils"]
    F --> G["Amyloid Plaques"]

    C -->|"Primary nucleation"| H["Soluble Oligomers<br/>ADDLs"]
    H -->|"Secondary nucleation"| I["More Oligomers"]
    I -->|"Toxic"| J["Synaptic Dysfunction"]
    I -->|"Toxic"| K["Oxidative Stress"]
    I -->|"Toxic"| L["Calcium Dyshomeostasis"]
    I -->|"Toxic"| M["Mitochondrial Dysfunction"]
    I -->|"Toxic"| N["Neuroinflammation"]

    style H fill:#3b1114,stroke:#c62828
    style I fill:#3b1114,stroke:#c62828

Aggregation Prone Regions

The central hydrophobic core (CHC, residues 17-21, KLVFF) is critical for:

• Steric zipper formation: Intermolecular β-sheet stacking

• Oligomerization: Dimer/trimer formation

• Fibril elongation: Monomer addition to fibril ends

The C-terminal hydrophobic tail (residues 30-42) drives:

• Membrane association: Hydrophobic interactions with lipid bilayers

• Fibril stability: Inter-protomer hydrogen bonds

Soluble Oligomers: The Toxic Species

Soluble Aβ oligomers (also called Aβ-derived diffusible ligands, ADDLs) are now recognized as the most toxic species, more so than mature fibrils or plaques^{3Soluble oligomers of the amyloid beta-protein impair synaptic plasticity (2008)2008 · DOI 10.1093/brain/awn130Open reference}. Key oligomer species include:

• Dimers: Smallest toxic unit, ~9 kDa

• Trimers: ~13.5 kDa, highly synaptotoxic

• Tetramers: ~18 kDa, may be “off-pathway”

• Dodecamers (Aβ*56): ~56 kDa, disrupts memory in mice

• Large oligomers: >100 kDa, membrane-permeable

Membrane-Mediated Effects

Aβ interacts with multiple membrane components:

1. Lipid rafts: Aβ accumulates in cholesterol-rich microdomains

2. Ion channels: Forms Ca²⁺-permeable pores

3. Receptors: Binds to NMDA, AMPA, insulin receptors

4. Membrane fluidity: Alters lipid organization

5. Synaptic vesicle: Impairs neurotransmitter release

Mechanisms of Neurotoxicity

Aβ exerts toxicity through multiple interconnected mechanisms:

1. Synaptic dysfunction: Aβ oligomers bind to synaptic receptors (PrPᶜ, NMDA, mGluR5), impairing long-term potentiation (LTP), reducing dendritic spine density, and disrupting neurotransmitter release^{4Amyloid-beta protein dimers impair memory (2008)2008 · DOI 10.1073/pnas.0804173105Open reference}

2. Oxidative stress: Aβ accumulation increases reactive oxygen species (ROS) production through:

   • Mitochondrial complex III dysfunction

   • NADPH oxidase activation

   • Metal redox cycling (Fe²⁺/Cu⁺ oxidation)

   • Lipid peroxidation

3. Neuroinflammation: Aβ activates microglia and astrocytes through:

   • TLR2/4 pattern recognition receptor activation

   • NLRP3 inflammasome activation

   • Cytokine/chemokine release (IL-1β, TNF-α, IL-6)

   • Chronic inflammation contributes to neurodegeneration

4. Calcium dysregulation: Aβ forms calcium-permeable channels in membranes:

   • Uncontrolled Ca²⁺ influx

   • Mitochondrial calcium overload

   • Calpain activation

   • Apoptosis signaling

5. Mitochondrial dysfunction: Aβ localizes to mitochondria:

   • Impairs complex IV activity

   • Reduces ATP production

   • Increases ROS

   • Triggers mitophagy deficits

6. Endoplasmic reticulum stress: Aβ disrupts protein folding:

   • UPR activation

   • CHOP-mediated apoptosis

   • Calcium store depletion

7. Autophagy impairment: Aβ disrupts autophagic flux:

   • mTORC1 hyperactivation

   • Lysosomal dysfunction

   • Autophagosome accumulation

See also: Amyloid Aggregation, Amyloid Hypothesis, and Amyloid-Tau Synergistic Interaction.

APP Processing and Genetic Risk

Amyloid precursor protein (APP) processing determines Aβ production:

Non-Amyloidogenic Pathway (Protective)

The non-amyloidogenic pathway is the default processing route in healthy brains:

• α-secretase cleavage: ADAM10/ADAM17 cleave APP at residue 16 (within the Aβ sequence)

• sAPPα release: Produces soluble APPα, which has neuroprotective properties

• CTFα formation: Creates a membrane-bound C-terminal fragment

• γ-secretase processing: CTFα is further processed to p3 peptide (non-amyloidogenic)

The sAPPα fragment:

• Promotes neurite outgrowth

• Enhances synaptic plasticity

• Has anti-inflammatory properties

• Protects against excitotoxicity

Amyloidogenic Pathway (Pathogenic)

The amyloidogenic pathway generates Aβ peptides:

• β-secretase (BACE1) cleavage: First cleavage at residue 1 of Aβ (APP residue 681)

• sAPPβ release: Soluble APPβ fragment

• CTFβ formation: C-terminal membrane fragment

• γ-secretase cleavage: Multiple cleavage sites produce Aβ38-43

γ-secretase cleavage sites:

• ε-site: Releases Aβ46-49 (longer fragments)

• γ-site: Produces Aβ38-43 isoforms

• ζ-site: Alternative cleavage

Genetic Risk Factors

APP Mutations (Autosomal Dominant)

Protective APP Variants

• A673V (Icelandic): Reduces Aβ production by 40%, carriers have 5x lower AD risk^{5Lecanemab clearance and efficacy (2023)2023 · DOI 10.1038/s41591-023-02318-1Open reference}

• A673T: Protective in vitro

APP copy number variants:

• Duplication syndrome: APP triplication causes early-onset AD with CAA

• Down syndrome: Extra APP copy leads to early Aβ accumulation

Genetic Risk Modifiers

• BIN1: Affects Aβ trafficking and aggregation

• PICALM: Modulates endocytosis and Aβ production

• CLU (Clusterin): Aβ chaperone, genetic risk factor

• ABCA7: Aβ clearance, lipid metabolism

Aβ Clearance Mechanisms

The brain has multiple pathways for Aβ clearance:

Proteolytic Degradation

Endogenous Aβ-degrading enzymes:

• Neprilysin (NEP): Primary Aβ-degrading enzyme in brain

  • Expression decreases with age

  • NEP overexpression reduces plaques in mice

  • AAV-mediated NEP delivery in clinical trials

• Insulin-degrading enzyme (IDE): Aβ and insulin degradation

  • Located in cytoplasm, mitochondria, and extracellular space

  • Genetic variants affect AD risk

• Matrix metalloproteinases (MMPs): MMP-2, MMP-9 degrade Aβ

  • Activated in glia

  • Increased in AD brain

• Plasmin: Broad-spectrum protease

  • Activated by tPA

  • Lower in AD CSF

• Cathepsins: Lysosomal proteases

  • Cathepsin B: Inhibited by cystatin C

  • Cathepsin D: Active in lysosomes

Microglial Clearance

Microglia clear Aβ through:

1. Receptor-mediated phagocytosis

   • TLRs (Toll-like receptors)

   • RAGE (Receptor for Advanced Glycation Endproducts)

   • SR-A (Scavenger Receptor A)

   • CD36 (class B scavenger receptor)

2. Autophagy-lysosomal degradation

   • LC3-associated phagocytosis (LAP)

   • PICALM involvement

   • Damaged lysosomes impair clearance

3. Aβ export across the blood-brain barrier

   • LRP1 (Low-density lipoprotein receptor-related protein 1)

   • P-glycoprotein (ABCB1)

   • Age-related export decline

Peripheral Clearance

Peripheral Aβ affects brain Aβ through the “peripheral sink” hypothesis:

• Liver and kidney clearance: Circulating Aβ degradation

• Monocyte/macrophage uptake: Phagocytic clearance

• Antibody-mediated clearance: Immunotherapy mechanisms

• LDL receptor family: Aβ binding and clearance

Sleep and Glymphatic Clearance

The glymphatic system is critical for Aβ clearance:

• Astrocytic AQP4 channels: Water flux

• Arterial pulsation: Driving force

• Sleep-dependent clearance: 60% more clearance during sleep

• Aβ diurnal variation: Higher during wakefulness

• Sleep disruption: Increases Aβ accumulation

Cellular and Animal Models

In Vitro Models

• Cell lines: CHO, HEK293, N2a for APP processing

• Primary neurons: Mouse, rat, human

• iPSC-derived neurons: Patient-specific models

• 3D neuronal cultures: Cerebral organoids

• Blood-brain barrier models: Transwell systems

In Vivo Models

Transgenic Mouse Models

Key Findings from Models

• Aβ oligomers cause synaptic dysfunction before plaques

• Microglial activation precedes plaque formation

• Tau pathology is required for full neurodegeneration

• Aβ vaccination reduces plaques but not always cognitive decline

Non-Murine Models

• C. elegans: Simplest model for aggregation studies

• Drosophila: Express Aβ in fly brain

• Zebrafish: Transparent model for development

• NHPs (non-human primates): Closest to human physiology

Clinical Trials and Therapeutic Challenges

Aβ-targeting therapies have faced challenges:

Completed trials (unsuccessful):

• Passive immunization (bapineuzumab, solanezumab)

• Active immunization (AN1792)

• γ-secretase inhibitors

• BACE1 inhibitors

Lessons learned:

• Early intervention may be critical

• Biomarker selection matters

• Target engagement necessary

• Combination approaches needed

Ongoing strategies:

• Anti-oligomer antibodies

• Small molecule aggregation inhibitors

• Vaccine approaches with improved design

• Aβ clearance enhancement

See also: Anti-Amyloid Therapeutics.

Role in Disease

Amyloid-beta (Aβ) is implicated in the following neurodegenerative conditions:

• Alzheimer’s Disease - the predominant component of amyloid plaques

• Cerebral Amyloid Angiopathy - vascular amyloid deposits

• Down syndrome - triplication of APP gene leads to early Aβ accumulation

• Dutch hereditary cerebral amyloid angiopathy - APP mutation causes severe CAA

• Arctic mutation - Aβ point mutation (E22G) causes aggressive Aβ aggregation

Amyloid Cascade Hypothesis

The amyloid cascade hypothesis, proposed by Hardy and Higgins in 1992, remains the dominant framework for understanding AD pathogenesis^{6Selkoe & Hardy, The amyloid hypothesis of Alzheimer's disease at 25 years (2016)2016 · DOI 10.1002/emmm.201210113Open reference}:

1. Aβ accumulation precedes tau pathology

2. Aβ triggers downstream tau hyperphosphorylation

3. Neurofibrillary tangles form

4. Neuronal loss and cognitive decline follow

Despite clinical trial failures, the hypothesis has evolved:

• Modified view: Aβ triggers, but tau drives neurodegeneration

• Oligomer-centric: Soluble oligomers, not plaques, are toxic

• Temporal model: Aβ effects are age-dependent and cumulative

Misfolding, aggregation, or dysfunction of Amyloid-beta (Aβ) contributes to neuronal damage through various mechanisms including proteotoxic stress, disrupted cellular signaling, and neuroinflammation.

Aβ in Down Syndrome (Trisomy 21)

Individuals with Down syndrome develop AD-like pathology by age 40-50:

• APP triplication: Chromosome 21 carries extra APP copy

• Aβ overexpression: 1.5x normal Aβ production

• Early plaques: Aβ plaques appear in 20s-30s

• Dementia risk: 50-70% develop dementia by age 60+

See also: Down Syndrome Alzheimer’s Disease.

Therapeutic Targeting

Amyloid-beta (Aβ) represents an important therapeutic target. Multiple drug development programs are exploring strategies to:

1. Reduce Production

BACE1 Inhibitors

• Verubecestat (MK-8931): Failed in Phase 3 — too much target engagement caused cognitive worsening

• Atabecestat: Failed due to liver toxicity

• Challenge: BACE1 processes many other substrates critical for synaptic function

γ-Secretase Modulators (GSMs)

• Notch-sparing modulators: Reduce Aβ42 production without Notch inhibition

• Chronic use potential: More tolerable than inhibitors

• Natural compounds: Some NSAIDs act as GSMs

2. Enhance Clearance

Passive Immunization

• Lecanemab (Leqembi): FDA-approved, binds Aβ protofibrils, 27% slowing of cognitive decline^{7Lecanemab in Early Alzheimer's Disease (2023)2023 · DOI 10.1056/NEJMoa2212948Open reference}

• Donanemab (Kisunla): FDA-approved, targets pyroglutamate-modified Aβ

• Gantenerumab: Failed in Phase 3 (Gradear)

• Aduhelm (aducanumab): Controversial FDA approval, withdrawn from market

Active Immunization

• ACI-35 (Lipidated tau): Phase 2 — anti-phospho-tau vaccine

• ABvac40: Phase 2 — targets Aβ40

• CAD106: Phase 2/3 — targets Aβ1-6

3. Inhibit Aggregation

Small Molecule Inhibitors

• Curcumin: Natural polyphenol, binds Aβ, anti-inflammatory

• Epigallocatechin gallate (EGCG): Green tea catechin, disrupts oligomers

• Broussoflavonol: Natural compound in paper mulberry

• Anle138b: Triple aromatic compound, blocks oligomer formation^{8Anle138b blocks Aβ oligomer formation (2019)2019 · DOI 10.1093/brain/awz085Open reference}

Metal Chelators

• Clioquinol: Cu/Zn chelator, reduces Aβ toxicity

• PBT2: Second-generation chelator, failed in Phase 2

4. Target Downstream Effects

• Anti-inflammatory: Anti-TNFα, NSAIDs (failed in prevention trials)

• Neuroprotective: AMPA modulators, neurotrophic factors

• Synaptic restoration: BDNF analogs, M1 agonists

• Metabolic support: GLP-1 agonists, metabolic enhancers

5. Emerging Approaches

Anti-Aβ Oligomer Antibodies

• ACI-302: Preferentially targets toxic oligomers

• BACI: Bispecific antibody approach

Aβ Degradation Enhancers

• Neprilysin enhancement: Endogenous Aβ-degrading enzyme

• IDE (insulin-degrading enzyme): Aβ clearance

• Matrix metalloproteinases (MMPs): Aβ degradation

Peripheral Sink Strategies

• Anti-peripheral Aβ antibodies: “Peripheral sink” hypothesis

• Albumin-based approaches: Bind plasma Aβ, shift equilibrium

See also: Anti-Amyloid Therapeutics, Amyloid-Beta 40 Biomarker, Amyloid-Beta 42/40 Ratio.

Key Publications

1. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science, 2002.

2. Amyloid-beta peptide — a chemist’s perspective. Angew Chem Int Ed, 2009.

3. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Brain, 2008.

4. Lecanemab in Early Alzheimer’s Disease. NEJM, 2022.

External Links

• UniProt: https://www.uniprot.org/uniprot/P05067

• AlphaFold: Amyloid-beta (Aβ)

• PDB: 1IYT, 1BA4, 2BEG, 5OQV

Brain Atlas Resources

• Allen Human Brain Atlas: Expression data for APP

• Allen Brain Atlas API: Gene expression via BrainAtlas API

• BrainSpan Atlas: Developmental expression of APP

See Also

• Proteins Index

• Genes Index

• Diseases Index

• Mechanisms Index

• APP Gene

• Alzheimer’s Disease

• Amyloid Cascade Hypothesis

• Amyloid Aggregation

Aβ Peptide Variants

Multiple Aβ peptide species exist due to alternative γ-secretase cleavage:

Major Species

Aβ42/Aβ40 Ratio

• Elevated Aβ42/Aβ40 ratio increases aggregation risk

• APP mutations can shift production toward Aβ42

• The ratio is a biomarker for AD risk

truncAβ Species

• N-terminally truncated Aβ (pE3-Aβ42, pE11-Aβ42)

• More aggregation-prone

• Found in early-onset AD and CAA

Aβ Biomarkers

Cerebrospinal Fluid (CSF) Biomarkers

Blood-Based Biomarkers

• Aβ42/Aβ40 ratio: Plasma ratio shows promise for screening

• p-tau181, p-tau217, p-tau231: Phospho-tau isoforms correlate with Aβ burden

• Neurofilament light (NfL): Axonal damage marker

• GFAP: Astrocyte activation marker

Imaging Biomarkers

• Amyloid PET (PiB, Florbetapir, Florbetaben): Visualizes plaque burden

• Florbetapir F-18 (Amyvid): FDA-approved for clinical use

• Amyloid load correlates poorly with cognition: Supports oligomer hypothesis

See also: Amyloid-Beta 42/40 Ratio, Amyloid PET Imaging, p-tau217.